P4, N=86, Not yet recruiting, Washington University School of Medicine

Compound 2 involves activating fluorescence by targeting tumor markers COX-2 as well as enhancing therapeutic efficacy. We believe this approach could provide insights for advancing cancer diagnosis and treatment technologies.

Collectively, these data define a molecular continuum from chronic gastritis to GC and highlight LIFR, IL10RB, SERPINE1 and HGF as pivotal biological macromolecules and candidate therapeutic targets. The repurposing potential of anti-inflammatory agents, particularly rofecoxib and nabumetone, suggests a feasible strategy to intercept the gastritis-carcinoma sequence.

P2, N=0, Withdrawn, Allodynic Therapeutics, Inc | N=300 --> 0 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2026 --> Dec 2025

A nuclear factor-kappa B (NF-κB) inhibitor, BAY11-7082, and a cyclooxygenase 2 (COX2) inhibitor, celecoxib, significantly inhibited PGE2 secretion, indicating that NF-κB and COX2 played a crucial role in reovirus-induced PGE2 production. These results indicate that reovirus replication in tumor cells is important for reovirus-induced PGE2 production. Attention should be paid to possible PGE2 production in tumors following reovirus treatment.

P1/2, N=80, Recruiting, Tanta University | Not yet recruiting --> Recruiting

PCSK9 promoted HCC immune escape by upregulating SPP1 and PD-L1 via NOTCH3/FLI1 signaling. CRISPR ABE-mediated PCSK9 deficiency and PCSK9 inhibitor parecoxib may serve as effective strategies to inhibit HCC.

P1/2, N=80, Not yet recruiting, Tanta University

CDS should be considered in cases of acute pain in the neck or occipital regions. Moreover, prompt computed tomography of the cervical vertebrae may guide early diagnosis and avoid unnecessary invasive procedures or administration of antibiotics.

P2/3, N=52, Completed, Kastamonu University | Not yet recruiting --> Completed

This study underscored COX-2 as a critical regulator of inflammatory microenvironment and cancer progression in ESCA, supporting its potential as both a prognostic biomarker and therapeutic target. The use of COX-2 inhibitors, such as celecoxib, holds promise for improving patient outcomes in ESCA and other COX-2-associated cancers.